Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHOP-ASO
- Development stage
- Preclinical
- Lead developer
- Secarna Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
CHOP-ASO is a locked nucleic acid (LNA)-modified antisense oligonucleotide (ASO) designed to target and reduce the expression of C/EBP homologous protein (CHOP, also known as DDIT3), a cell-death-promoting transcription factor and key mediator of the endoplasmic reticulum (ER) stress response. Developed by Secarna Pharmaceuticals using its proprietary LNAplus™ platform, CHOP-ASO is designed to address diseases driven by maladaptive ER stress, particularly diabetic kidney disease (DKD) / diabetic nephropathy. In preclinical models, CHOP-ASO has demonstrated the ability to reduce renal CHOP expression, ameliorate glomerular and tubular damage, and provide synergistic therapeutic benefits when combined with angiotensin-converting enzyme inhibitors (ACEi).
- Other names
- ChACHOP antisense oligonucleotideChop-ASOLNA-modified antisense oligonucleotide targeting CHOPLNAplus antisense oligonucleotide targeting CHOP
02
Targets
ChoP (Phosphorylcholine)
Beyond the preview
Go deeper on CHOP-ASO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHOP-ASO.